United Advisor Group LLC Makes New $308,000 Investment in Amgen Inc. (NASDAQ:AMGN)

United Advisor Group LLC bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,182 shares of the medical research company's stock, valued at approximately $308,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Beck Mack & Oliver LLC increased its holdings in shares of Amgen by 0.7% during the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock worth $1,205,000 after buying an additional 34 shares in the last quarter. Continuum Advisory LLC increased its stake in shares of Amgen by 0.7% in the 4th quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company's stock valued at $1,343,000 after buying an additional 35 shares during the period. Blossom Wealth Management boosted its holdings in Amgen by 3.5% in the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock valued at $284,000 after acquiring an additional 37 shares during the last quarter. Zullo Investment Group Inc. lifted its position in Amgen by 2.8% during the 4th quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock valued at $356,000 after purchasing an additional 37 shares during the period. Finally, Trillium Asset Management LLC grew its position in shares of Amgen by 4.2% during the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after buying an additional 37 shares during the period. Institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

AMGN has been the subject of several analyst reports. Mizuho boosted their target price on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Royal Bank of Canada dropped their price target on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Cantor Fitzgerald assumed coverage on Amgen in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 target price on the stock. Finally, Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $309.22.

Amgen Stock Performance

NASDAQ AMGN traded up $5.14 on Thursday, reaching $283.54. The stock had a trading volume of 2,801,720 shares, compared to its average volume of 2,801,334. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a fifty day moving average of $284.48 and a two-hundred day moving average of $285.76. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a market cap of $152.46 billion, a P/E ratio of 37.56, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The business had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the previous year, the firm earned $3.96 earnings per share. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date is Friday, May 16th. Amgen's payout ratio is 86.86%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.